Research programme: TNF receptor antagonists - Fulcrum Pharmaceuticals
Alternative Names: TNF receptor antagonists research programme - Fulcrum PharmaceuticalsLatest Information Update: 07 Mar 2011
At a glance
- Originator Fulcrum Pharmaceuticals
- Class Small molecules
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 22 Feb 2005 Preclinical trials in Inflammation in USA (PO)
- 22 Feb 2005 Preclinical trials in Psoriasis in USA (PO)
- 13 Jul 2004 Preclinical trials in Rheumatoid arthritis in USA (PO)